Search clinical trials for: Influenza vaccine (FLU-v)

Total 1105 results

University of Wisconsin, Madison

Completed

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Influenza

United States
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Human Influenza

Kazakhstan
PharmaJet, Inc.

Completed

Inactivated Influenza Via Jet Injection (IIJI)

Influenza, Human

United States
Abt Associates
Centers for Disease Control and Prevention; Clalit Research Institute

Unknown

Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel (HCP)

Influenza | Respiratory Tract Disease

Israel
GlaxoSmithKline

Completed

Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine

Influenza

Czech Republic
National Institute of Allergy and Infectious Diseases...

Recruiting

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Influenza

United States
McMaster University
Canadian Institutes of Health Research (CIHR)

Completed

Live Versus Inactivated Influenza Vaccine Study in Hutterite Children

Influenza

Canada
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

Influenza

United States
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Prevention | Pandemic Influenza | Pandemic Influenza Vaccine

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Healthy Volunteers | Influenza Immunization

United States
Mahidol University
World Health Organization; The Government Pharmaceutical Organization

Completed

Safety and Immunogenicity of Live Attenuated Influenza H5N2

Influenza Due to Influenza A Virus Subtype H5N2

Thailand
University of Oxford

Completed

Swine Flu (Influenza A H1N1) Follow on Vaccine Study

Influenza

United Kingdom
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011

Seasonal Influenza

Italy
University of Alabama at Birmingham

Active, not recruiting

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Influenza

United States
Hadassah Medical Organization

Unknown

Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem

HIV Infections | Influenza | Acquired Immune Deficiency Syndrome

Israel
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
Novartis Vaccines

Completed

Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers

Seasonal Influenza

Vietnam
University of British Columbia
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR)

Completed

Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011 (PCIRNRT06)

Influenza

Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France
Abramson Cancer Center at Penn Medicine

Recruiting

BRCA1/2 Flu Vaccine

BRCA1 Mutation | BRCA2 Mutation

United States
Butantan Institute

Completed

Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018) (FLU-06-IB)

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Physiological Effects of Drugs | Vaccines

Brazil
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Novartis Vaccines

Completed

Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases

Influenza Disease

Italy
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Brief Influenza Vaccine Education to Pregnant Women

Pregnancy | Infectious Disease | Influenza

Hong Kong
Tel-Aviv Sourasky Medical Center

Unknown

Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

Rheumatoid Arthritis | Cellular Immune Response

Israel
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

Leukemia | Infection

United States
Northwestern University

Completed

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

Influenza

United States
Universitas Padjadjaran
Universiti Sains Malaysia; Biofarma

Completed

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Diabetes Mellitus | Chronic Kidney Diseases | Vaccine Reaction | Influenza

Indonesia
University of Pennsylvania

Active, not recruiting

Flu Vaccine Responses in the Setting of Melanoma Treatment

Viral Vaccines

United States
Novartis Vaccines

Completed

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Seasonal Influenza

Italy
Jiangsu Province Centers for Disease Control and...

Completed

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Influenza

China
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
University of Michigan
American College of Allergy, Asthma and Immunology

Completed

Safe Administration of Flu Vaccine to Egg Allergic Children (SAFE)

Egg Allergy

United States
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Influenza, Human

Kazakhstan
Novartis Vaccines

Completed

Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.

Influenza Disease

Italy
Seqirus

Completed

Phase II Study of Pandemic Influenza Vaccine

Influenza

Australia
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Interpandemic Influenza

Italy
Crucell Holland BV

Completed

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
National Institute of Allergy and Infectious Diseases...
Baylor College of Medicine; University of Pittsburgh; Ann & Robert H Lurie Children... and other collaborators

Not yet recruiting

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (PSOT)

Influenza | Transplantation Infection | Immunization; Infection

United States
Vanderbilt University Medical Center
University of Alabama at Birmingham; Duke University; University of Washington; Northwestern University Feinberg School of Medicine

Recruiting

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Influenza | Transplantation Infection | Immunization; Infection

United States
Bayer
CureVac

Withdrawn

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
Johns Hopkins University
Department of Health and Human Services

Completed

Influenza Diagnosis, Treatment and Surveillance With Xpert Flu

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Canada, United States

3

Subscribe